Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis - PubMed (original) (raw)

Meta-Analysis

. 2007 Jul 1;110(1):38-46.

doi: 10.1002/cncr.22754.

Affiliations

• PMID: 17520704
• DOI: 10.1002/cncr.22754

Free article

Meta-Analysis

Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis

Ju-Han Lee et al. Cancer. 2007.

Free article

Abstract

Background: Numerous studies have investigated the clinical significance of BRAF mutation in papillary thyroid carcinoma (PTC). However, there have been conflicting data on the usefulness of BRAF mutation as a prognostic marker of PTC. To address this controversy, the frequency of the BRAF mutation and the associations between BRAF mutation and clinicopathologic parameters in PTC were evaluated by meta-analysis.

Methods: The relevant published studies were reviewed according to the defined selection criteria. The effect sizes of outcome parameters were estimated by odds ratio or weighted mean difference.

Results: The current meta-analysis included 12 studies with a total of 1168 patients. The frequency of the BRAF mutation was 49%. The BRAF mutation was associated with histologic subtype, the presence of extrathyroidal extension, and higher clinical stage, but not with age, sex, race, or tumor size.

Conclusions: The effect of the BRAF mutation on the poor prognosis of PTC patients was evident from the current meta-analysis. The detection of the BRAF mutation may be used as an important prognostic marker of patients with PTC.

Copyright (c) 2007 American Cancer Society.

PubMed Disclaimer

Similar articles

• BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases.
  Rodolico V, Cabibi D, Pizzolanti G, Richiusa P, Gebbia N, Martorana A, Russo A, Amato MC, Galluzzo A, Giordano C. Rodolico V, et al. Cancer. 2007 Sep 15;110(6):1218-26. doi: 10.1002/cncr.22912. Cancer. 2007. PMID: 17685465
• BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
  Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, García-Rostán G. Costa AM, et al. Clin Endocrinol (Oxf). 2008 Apr;68(4):618-34. doi: 10.1111/j.1365-2265.2007.03077.x. Epub 2007 Dec 5. Clin Endocrinol (Oxf). 2008. PMID: 18070147
• Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
  Erickson LA, Jin L, Nakamura N, Bridges AG, Markovic SN, Lloyd RV. Erickson LA, et al. Cancer. 2007 May 15;109(10):1965-71. doi: 10.1002/cncr.22641. Cancer. 2007. PMID: 17387744
• Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
  Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X. Quiros RM, et al. Cancer. 2005 Jun 1;103(11):2261-8. doi: 10.1002/cncr.21073. Cancer. 2005. PMID: 15880523 Review.
• BRAF mutations in papillary thyroid carcinoma.
  Wojciechowska K, Lewinski A. Wojciechowska K, et al. Endocr Regul. 2006 Dec;40(4):129-38. Endocr Regul. 2006. PMID: 17201587 Review.

Cited by

• Genetic Alterations in Hungarian Patients with Papillary Thyroid Cancer.
  Tobiás B, Halászlaki C, Balla B, Kósa JP, Árvai K, Horváth P, Takács I, Nagy Z, Horváth E, Horányi J, Járay B, Székely E, Székely T, Győri G, Putz Z, Dank M, Valkusz Z, Vasas B, Iványi B, Lakatos P. Tobiás B, et al. Pathol Oncol Res. 2016 Jan;22(1):27-33. doi: 10.1007/s12253-015-9969-9. Epub 2015 Aug 11. Pathol Oncol Res. 2016. PMID: 26259532
• Response to Treatment is Highly Predictable in cN0 Patients with Papillary Thyroid Carcinoma.
  Gorshtein A, Benbassat C, Robenshtok E, Shimon I, Hirsch D. Gorshtein A, et al. World J Surg. 2016 Sep;40(9):2123-30. doi: 10.1007/s00268-016-3507-0. World J Surg. 2016. PMID: 27094559
• Evaluation of the Role of _BRAF_V600E Somatic Mutation on Papillary Thyroid Cancer Disease Persistence: A Prospective Study.
  Damiani L, Lupo S, Rossi R, Bruni S, Bartolomei M, Panareo S, Franceschetti P, Carcoforo P, Lanza G, Pelucchi S, Degli Uberti E, Zatelli MC. Damiani L, et al. Eur Thyroid J. 2018 Oct;7(5):251-257. doi: 10.1159/000490699. Epub 2018 Jul 13. Eur Thyroid J. 2018. PMID: 30374428 Free PMC article.
• BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm.
  Silver JA, Bogatchenko M, Pusztaszeri M, Forest VI, Hier MP, Yang JW, Tamilia M, Payne RJ. Silver JA, et al. J Otolaryngol Head Neck Surg. 2021 Nov 6;50(1):63. doi: 10.1186/s40463-021-00543-9. J Otolaryngol Head Neck Surg. 2021. PMID: 34742355 Free PMC article.
• The BRAFV600E Mutation Is Not a Risk Factor for More Aggressive Tumor Behavior in Radiogenic and Sporadic Papillary Thyroid Carcinoma at a Young Age.
  Zurnadzhy L, Bogdanova T, Rogounovitch TI, Ito M, Tronko M, Yamashita S, Mitsutake N, Chernyshov S, Masiuk S, Saenko VA. Zurnadzhy L, et al. Cancers (Basel). 2021 Nov 30;13(23):6038. doi: 10.3390/cancers13236038. Cancers (Basel). 2021. PMID: 34885148 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Molecular Biology Databases

  • GlyGen glycoinformatics resource

• Research Materials

  • NCI CPTC Antibody Characterization Program